CNMV.-ALMIRALL, S.A. Otros sobre negocio y situación financiera
MADRID, 29 Sep. (CNMV) - Almirall announces positive phase III results showing efficacy of LAS41008 (dimethyl fumarate), a new systemic oral drug for patients with chronic plaque psoriasis